Authors
AFIFI, A. M., ADNAN, M., TAHA, M., and AMASHA, M. E.: Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies ALI-KHAN, G.: Treatment of anxiety-related insomnia with chlormezanone ALBIZZATI, M. G., BASSI, S., BINDA, G., and PASSERINI, D.: Effects of vincamine on EEG sleep patterns in man: a pilot study
ANDERSSON, P. O., HACKL, H., JENSEN, P., and LARSEN, K. R.: A comparison of two different dosages of pivampicillin and doxycycline in patients with gynaecological infections
ANGELKORT, B., MAURIN, N., and BOATENG, K.: Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease
BACKHOUSE, C. I.: Intra-nasal flunisolide in the treatment of allergic rhinitis in general practice BAKER, P. G., and GOULTON, J.: A multicentre study of twice daily accounted to the study of the study of twice daily accounted to the study of the
('Sectral') in the treatment of hypertension in general practice BALL, A. J., EVANS, P. J., and FOSTER, M. E.: Intra-incisional cephaloridine: a
comparison of two methods of administration BALOGH, Zsolt, PAPAZOGLOU, Sotirios N., MACLEOD, Marion and BUCHANAN, Watson W.: A crossover clinical trial of piroxicam, indomethacin and ibuprofen in
rheumatoid arthritis BARRINGTON, R.: Single-blind study of diflunisal versus mefenamic acid in the treatment of pain after Colles' fracture
BEREND, N., RUTLAND, J., and MARLIN, G. E.: Plasma and saliva concentrations for a new formulation of erythromycin stearateBIEHL, B.: Effects of azatadine maleate on subjective appraisal and psychomotor func-
tions relevant to driving performanceBIGNAMINI, A. A., and CASULA, P. L.: Preliminary bioavailability study on protacine:
a new, non-steroidal anti-inflammatory agent BORNSTEIN, S.: Cross-over trial comparing the antidepressant effects of amineptine and maprotiline
BOTTER, P. A.: Single daily dose treatment of anxiety with clobazam: a double-blind study versus normal multiple-dose treatment with diazepam BRIGGS, M. H., and BRIGGS, Maxine: Plasma lipoprotein changes during oral
contraception BRØRS, O., FAUCHALD, P., LIND, E., and JACOBSEN, S.: Pharmacokinetics and saluretic effect of muzolimine in severe cardiac failure
BRUSASCO, V., CRIMI, E., MANGINI, S., and VIBELLI, C.: A clinical trial of oral clenbuterol (NAB 365) in chronic airways obstruction BULLEN, B. R., RAMSDEN, C. H., and KESTER, R. C.: Evaluation of tissue levels of
cefamandole in severely ischaemic lower limbs using two regimens of dosage, : Tissue levels of cephradine in ischaemic limbs following a single intravenous injection
BULLOUGH, J.: Use of povidone-iodine alcoholic solution in the treatment of herpes genitalis: a preliminary study
CASTRO, M.: Xipamide ('Diurexan') in essential hypertension: a 24-month study, and REYES, A. J.: Mathematical model of the time-course of essential hypertension blood pressure changes during chronic xipamide treatment
CHEADLE, A. J., and FREEMAN, H. L.: Pimozide in the maintenance treatment of apathetic and emotionally withdrawn schizophrenics COCKRAM, C. S., RICHARDS, Peter, and BAX, R. P.: The safety of cefuroxime and
gentamicin in patients with reduced renal function
DAFTARY, S. N., MEHTA, A. C., and NANAVATI, M.: A controlled comparison of dipyrone and paracetamol in post-episiotomy pain
ous allergic diseases DE LOORE, F., HECK, E., VAN EYGEN, M., and CASNEUF, J.: Levamisole (R12564) in the prevention of recurrent upper respiratory tract infections in children: a double blind allegable controlled ctudy.
double-blind, placebo-controlled study
DEL BONO, N., QUARTIERI, F., and VIBELLI, C.: Aerosolized clenbuterol (NAB

Authors
AFIFI, A. M., ADNAN, M., TAHA, M., and AMASHA, M. E.: Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies ALI-KHAN, G.: Treatment of anxiety-related insomnia with chlormezanone ALBIZZATI, M. G., BASSI, S., BINDA, G., and PASSERINI, D.: Effects of vincamine on EEG sleep patterns in man: a pilot study
ANDERSSON, P. O., HACKL, H., JENSEN, P., and LARSEN, K. R.: A comparison of two different dosages of pivampicillin and doxycycline in patients with gynaecological infections
ANGELKORT, B., MAURIN, N., and BOATENG, K.: Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease
BACKHOUSE, C. I.: Intra-nasal flunisolide in the treatment of allergic rhinitis in general practice BAKER, P. G., and GOULTON, J.: A multicentre study of twice daily accounted to the study of the study of twice daily accounted to the study of the
('Sectral') in the treatment of hypertension in general practice BALL, A. J., EVANS, P. J., and FOSTER, M. E.: Intra-incisional cephaloridine: a
comparison of two methods of administration BALOGH, Zsolt, PAPAZOGLOU, Sotirios N., MACLEOD, Marion and BUCHANAN, Watson W.: A crossover clinical trial of piroxicam, indomethacin and ibuprofen in
rheumatoid arthritis BARRINGTON, R.: Single-blind study of diflunisal versus mefenamic acid in the treatment of pain after Colles' fracture
BEREND, N., RUTLAND, J., and MARLIN, G. E.: Plasma and saliva concentrations for a new formulation of erythromycin stearateBIEHL, B.: Effects of azatadine maleate on subjective appraisal and psychomotor func-
tions relevant to driving performanceBIGNAMINI, A. A., and CASULA, P. L.: Preliminary bioavailability study on protacine:
a new, non-steroidal anti-inflammatory agent BORNSTEIN, S.: Cross-over trial comparing the antidepressant effects of amineptine and maprotiline
BOTTER, P. A.: Single daily dose treatment of anxiety with clobazam: a double-blind study versus normal multiple-dose treatment with diazepam BRIGGS, M. H., and BRIGGS, Maxine: Plasma lipoprotein changes during oral
contraception BRØRS, O., FAUCHALD, P., LIND, E., and JACOBSEN, S.: Pharmacokinetics and saluretic effect of muzolimine in severe cardiac failure
BRUSASCO, V., CRIMI, E., MANGINI, S., and VIBELLI, C.: A clinical trial of oral clenbuterol (NAB 365) in chronic airways obstruction BULLEN, B. R., RAMSDEN, C. H., and KESTER, R. C.: Evaluation of tissue levels of
cefamandole in severely ischaemic lower limbs using two regimens of dosage, : Tissue levels of cephradine in ischaemic limbs following a single intravenous injection
BULLOUGH, J.: Use of povidone-iodine alcoholic solution in the treatment of herpes genitalis: a preliminary study
CASTRO, M.: Xipamide ('Diurexan') in essential hypertension: a 24-month study, and REYES, A. J.: Mathematical model of the time-course of essential hypertension blood pressure changes during chronic xipamide treatment
CHEADLE, A. J., and FREEMAN, H. L.: Pimozide in the maintenance treatment of apathetic and emotionally withdrawn schizophrenics COCKRAM, C. S., RICHARDS, Peter, and BAX, R. P.: The safety of cefuroxime and
gentamicin in patients with reduced renal function
DAFTARY, S. N., MEHTA, A. C., and NANAVATI, M.: A controlled comparison of dipyrone and paracetamol in post-episiotomy pain
ous allergic diseases DE LOORE, F., HECK, E., VAN EYGEN, M., and CASNEUF, J.: Levamisole (R12564) in the prevention of recurrent upper respiratory tract infections in children: a double blind allegable controlled ctudy.
double-blind, placebo-controlled study
DEL BONO, N., QUARTIERI, F., and VIBELLI, C.: Aerosolized clenbuterol (NAB

	Page
DEL ROSAL, Pedro Leal, DEL ROSAL, Luis Leal, CARRASCO, Alfredo G. Riosvelasco, and RASCON, Estela Aguirre: Comparison of sisomicin and gentamicin in the treatment of conjunctive treatment of the conference of t	663
in the treatment of serious systemic infections DEODHAR, Shridhar D., and SETHI, Ranjit: A comparative study of fenbufen and	663
indomethacin in patients with rheumatoid arthritis DEQUEKER, J., STEVENS, E., and WUYTS, L.: A controlled trial of magnesium	263
dithiosalicylate compared with aspirin in rheumatoid arthritis DHEM, A., ARS-PIRET, N., and WATERSCHOOT, M. P.: The effect of nandrolone	589
decanoate on rarefying bone tissue DONNELLY, T., and HARROWER, A. D. B.: Effect of nifedipine on glucose tolerance	606
and insulin secretion in diabetic and non-diabetic patients	690
EMANUELI, A., MANDELLI, V., MASCELLANI, G., and SACCHETTI, G.: Indopprofen, a new non-steroidal anti-inflammatory drug, in the treatment of osteoarthrosis: report on a multi-centre study in 1629 patients	124
EVANS, C. M., CLARKE, T. K., BARNOUTI, H., CROSBY, A. C., HOLMES, S., and KULATILAKE, A. E.: A controlled trial of different treatment regimens in patients	
with urinary tract infections after lower urinary tract surgery EVANS, D. P., BURKE, M. S., and NEWCOMBE, R. G.: Medicines of choice in low back pain.	386 540
FORREST, W. A.: Use of a sustained-release formulation of oxprenolol and cyclo-	
penthiazide ('Trasidrex') in the management of hypertension: a general practice study _ FRASCHINI, F., AVALLON, R., COPPONI, V., FUMAGALLI, G., MANDLER, F.,	559
SCAGLIONE, F., and SCARPAZZA, G.: Bactericidal action of an average dose of erythromycin in the bronchi.	111
FRÁSER, N. B., MAIN, R. A., STEWART, T. W., and THORNTON, E. J.: Treatment of acne vulgaris comparing two similar lotion formulations, one with ('Actinae') and account to the comparing two similar lotion formulations.	461
one without chloramphenicol FREDRIKSSON, T., and NORDIN, K.: Clobetasone butyrate compared with beta- methasone valerate in the treatment of atopic and contact dermatitis	322
GHOSH, M. L., and TINGLE, A.: Platelet aggregation in patients treated with diffunisal GHOSN, S.: Evaluation of sodium stibogluconate in the treatment of cutaneous leish-	510
maniasis in Syria GIAMPIETRO, Ottavio, NAVALESI, Renzo, BUZZIGOLI, Giuseppe, and BONI, Claudio: Plasma levels of glucose and lactate after intravenous glipizide administration in some insulin-dependent diabetics. Therapeutic effects of an associated glipizide-	280
insulin treatment GOODFELLOW, R. M.: A fixed combination of metoprolol and hydrochlorothiazide for	325
hypertension: a multi-centre study GOMEZ, G., and PHILLIPS, L. A.: Labetolol ('Trandate') in hypertension: a multi-	371
centre study in general practice	677
tory arthritic conditions: a multi-centre study in general practice GUERRIER, C. J. W., and THORNTON, E. J.: Double-blind comparison of two similar lotion formulations, one without and the other with hydrocortisone acetate	423
('Actinac') in the treatment of acne vulgaris	377
HART, Alan J. L., MILES, R. S., VARNAM, D. J., and EDMOND, P.: Assessment of the morbidity and value of prophylactic cephazolin sodium in urinary tract instrumen-	4.50
tation in out-patients HARWART, D.: The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline ('Trental' 400).	658 73
HASAN, S. S.: Treatment of moderate to severe gastro-oesophageal reflux with an alginate/antacid combination	645
HAWARD, L. R. C.: Multivariate symptom analysis related to response to lorazepam treatment	20
HENRY, Mary, HANKS, Geoffrey, and WHELAN, Annette: A randomized, double-blind therapeutic trial of 0.25 % desoxymethasone and 0.1 % hydrocortisone 17-butyrate	
in the treatment of varicose eczema HOLDEN, J. M. C., KERRY, R. J., and ORME, J. E.: Amoxapine in depressive illness	502 338
HOLTI, G.: A double-blind study of the peripheral vasoconstrictor effects of the beta- blocking drug penbutolol in patients with Raynaud's phenomenon	267
HUDSON, I. N., DAVIDSON, I. A., HIDER, C. F., and WRIGHT, A. D. G.: The use of lorazenam in cardiac hypass surgery: a comparative study	303

ige
74
69
73
71
44
88
8
104
65
68
36
351
137
213
221
60
519
507
172
30
154
524
549
287 207
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3

	Page
PRIME, F. J., BIANCO, S., and KAMBUROFF, P. L.: Inhibition of artificially-induced asthma by reproterol ('Bronchospasmin')	364
REARDON, J. A., STOCKMAN, A., DARLINGTON, L. G., and SCOTT, J. T.: Double-blind trial of feprazone and phenylbutazone in acute gout REEVES, D. S., MORRIS, R. W., WATTS, M. R., and P.EEVES, R. E. T.: Double-blind clinical trial of a nitrofurantoin/sulphadiazine combination at two dosage levels in acute	445
symptomatic urinary infections REITERER, W.: Effects of long-term treatment with a beta-receptor blocker, pindolol, combined with a diuretic agent, clopamide, on exercise performance in hypertension	481 552
RICHARDS, J. G.: Doxycycline and amoxycillin in respiratory infections; a comparative assessment in general practice	393
SALAKO, L. A., FALASE, O. A., and ADEROUNMU, A. Fadeke: Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients SALTVEDT, E., and FAUCHALD, P.: Effect of single and twice daily doses of primidolol (UK-11, 443) in hypertension	358 528
SAMANTA, T. C., BAX, R. P., PEARSON, R. M., HAVARD, C. W. H., BRUMFITT, W., and HAMILTON-MILLER, J. M. T.: Clinical study of cefuroxime in the treatment of lower respiratory tract infections	466
SHARMA, J. N., and BUCHANAN, W. Watson: Kinin system in clinical and experimental rheumatoid inflammation: a short review	314 70
SHEE, C. D., and MEDD, W. E.: Stopping phenformin treatment in a diabetic clinic SIKLOS, P., and HENDERSON, R. G.: Severe acidosis from acetazolamide in a diabetic patient	201
SIMS, A. C. P.: Comparison of the efficacy of sustained-release amitriptyline with maprotiline in the treatment of depressive illness STAQUET, M. J.: Analgesic effect of ciramadol in patients with chronic pain.	534 475
Effect of parenteral dezocine and placebo in cancer pain. STEFANOVICH, V.: The role of biochemistry in drug research STEGER, W.: Treatment of hypertensive out-patients with a sustained-release dosage form of clonidine: a comparison with standard tablet therapy and long-term follow-up	634 488 670
study STIRLING, G. S.: Pimozide as a replacement for maintenance therapy in chronic schizophrenia STONEY, D. W.: Cefuroxime in post-operative chest infections	331 209
TORMEY, W. P., BUCKLEY, M. P., O'KELLY, D. A., CONBOY, J., PINDER, R. M., and DARRAGH, A.: Sleep-endocrine profile of the antidepressant mianserin _ TÖRÖK, E., WAGNER, M., ERDELYI, M., and MAKLARI, E.: Two-years' study with a combination of pindolol and clopamide ('Viskaldix') in patients with moderate hypertension	456 193
TUÖMILEHTÖ, Jaakko, NISSINEN, Aulikki, and ELO, Jyrki: Experience with labetalol in essential hypertension.	407
VAN AMERONGEN, P.: Double-blind clinical trial of the antidepressant action of amineptine VAN BRUMMELEN, P., LEUVEN, J. A. Gevers, and VAN GENT, C. M.: Influence	93
of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension	24
SWIERENGA, J.: Comparison of the speed of bronchodilator action after inhaled fenoterol and rimiterol in reversible airways obstruction VAUTERIN, C., and BAZOT, M.: A double-blind controlled trial of amineptine versus	183 101
trimipramine in depression	
hernia and peptic ulceration. WHEATLEY, D.: A study of non-articular rheumatic disorders and their response to treatment with naproxen sodium	85 229
WILLIAMS, B. O., and CARLYLE, D.: Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism WILLIAMSON, D. M., and GATECLIFF, M.: Effect of thymoxamine in the relief of	1
pain and rate of healing in ischaemic leg ulceration	500 685
ZEEDICK John F: A double-blind comparison of oral butorphanol and codeine	178

Subject														F	age
Acebutolol, in hy	pertens	sion		-						_			_		51
Acetazolamide, se	evere a	cidos	is in d	iabetes	i				-	-	_	_	-		284
Acne vulgaris, tre					rmula	ations				-	-	-	-	377,	
Adverse drug read	ctions,	aceta	zolam	iide	-	-	-	-	-	-					284
_, propranolol Airways obstructi	on tro	-	nt wit	h clonk	-	Loom	narad	with	torbut	Tino	***	-	-		207
_, _ fenoterol com					Jutere	oi com	pareu	WILL	terour	anne	-	****	-		183
Alginate/antacid	combi	natio	a. in g	astric a	and bi	lious	reflux	-	-	non-	-				645
Allergic disorders											-	-	_		380
_ rhinitis, treatme	nt with	h flun	isolide	3_	test:	-					-	-	Adres		14
Alprenolol, in hyp			_	_		_	_	-	4	-					358
Althiazide, combi								_	-		desc.	_			136
Amineptine, in de		on, co	ompar	ed wit	h ami	tripty	ine	-			_	_	-		93
_, _, _ maprotiline		-	-	-	-	-	-	-	-	_	-	_	_		107
Amitriptyline, in	denres	cion	comp	arad w	ith an	ninent	ine	-	-		-	-			101
_, _, maprotiline		SIUII,	compa	arcu w	itii aii	mept	inc				_	_			534
Amitriptyline/chl	ordiaz	enoxi	de coi	mbinat	ion. i	n den	ression	7.	-	-	-	-	-		573
Amoxapine, in de											-		-		338
Amoxycillin, in re								clor	_		_		_		569
_, _, _ doxycycline	e_	-	-		-	-		er.	-		-		_		393
Ampicillin, in res									-	-	-	-	_		564
Anaesthesia, indu							opent	one so	odium	-	-		-		30
Analgesics and an	ti-infla	amma	itory a	igents,	aspir	in	-	-			-	540,	589,	597,	
_, butorphanol	-	-	-	-	-	-		-	-	-	-	Miles	-		178
, ciramadol	-	-	-	deres	-	_	-	-	-	100	_	Berry	_		475 178
_, codeine _ _, dextropropoxy	nhana	nara	etam	alcom	hinati	ion	-	nen.	-	No.	-	-			540
_, dezocine _	prierie	parac	ctairi	oi com	Ulliat	1011	0-0		-	400-	-		_	472,	
_, diacetylrhein	_	_		_		_	_	-	-		-	_	_	11.009	548
_, diflunisal _				-		_		-					154.	510,	
_, dipyrone _		_	_	_	_	_	_	_	_			_	614,		
_, fenbufen _	-	100				~~		-		-	_	-	_		263
, feprazone	~		-		-	-		-	-	-	-	-	-		445
, ibuprofen	-			_	_	_	-	Along		_	river.	1 40	262	005	148
_, indomethacin		-	-	-	-		*100	-		-		148,	263,	287,	540
_, indoprofen	-	Acre.	-		-		-	Access	-	-	-	-	-	124,	423
_, ketoprofen _, magnesium ditl	nineali	cylate	-	ner.		-	-	mo	000		-	-	-		589
_, mefenamic acid		cylatt	-	-	-	-	-				-	-		540	614
_, naproxen sodiu	ım.	_	_	_	-	-	-	_	_	_			_	0,0,	229
_, paracetamol			_	~		-		-	_		_	_	-	540,	
_, pethidine _	_		_	-	No.	-	-	Area.	-	-	-	-	_		624
, phenylbutazon	e	_		-		-		-	-	-	_	-	_	445,	
, piroxicam	-00	-	200	-	in	-		-	-	-	-	-	-	205	148
_, protacine _	- ika at	-	-	_	-	-	-	$\overline{}$	-	-				287,	
Antibiotics and a	ntibaci	teriai	agent	s, amp	ICHIIII	_	-	-	-	*	-	-	-	202	564
_, amoxycillin _, cefaclor	Man.	-	-	200	-	Miles	-	2000	-		-	19-4	-	393, 564,	
_, cefamandole	-	-	Person	-	-	100		-	-	***		-	_	304,	244
_, cefuroxime		_	_	-	-	_		han.	-	~	209,	398.	404,	466.	
_, cephaloridine		-	-	-	3	_		-	-					,	204
_, cephazolin	-	_	_	_		_		3		-	net.		_		658
_, cephradine	_	100	-	-	-	_		-	-	-	-	-		386,	585
_, co-trimoxazole	_	-	-	_	-		-	-	-	-	-	-	_		386
_, doxycycline	-	-	-	-	-	-	-		-	-	-	-	-		513
_, erythromycin	-	-	-	-	-	***	-	-	Anna.	-	-	-	-		118
_, gentamicin _, mecillinam	-	-	-	-	-		~~	-	-	-	-	-		398,	221
_, nitrofurantoin/	sulpho	diazi	ne cor	nhinat	ion	-	dist	-	-	-	-	-	_		481
_, pivampicillin	Paihite	-unitial		om		-		-		-	-	-	-		513
_, sisomicin _		100	-	_	-	_	-				3				663
Anticoagulants, u	ise wit	h ben	fluore	x, in ca	ardiac	cond	itions						-		478
Antidepressive ag				_	-		-	_	-	_	-	-	93,	101,	, 107
_, amitriptyline	_			-	-	***	-	-	-			-	100		, 534
_, amitriptyline/c	hlordi	azepo	xide c	ombin	ation	-	-	~		-	-	_	_		573

														-
														Page
Antidepressive as	zents.	amox	anine											338
_, imipramine	5011109	unio.	- aprille		-	-	April 10	_			-	_	-	338
, maprotiline						BELO.		-		4.00	-	_	-	107, 534
			-	-		-	1000	***		4000		-	-	456
, mianserin		-	-				-	-	_		-	-	_	
_, trimipramine		11.1.11	15 0	_		-			witte	-	440	_	-	101
Antifungal agent	s, can	aicidii	1/3-114	orocyt	osine	comb	inatio	n	_	_	-	1000		88
, clotrimazole	-	-			-	400	-	100	-	1000	1000	100	(max)	88
Antihypertensive	agen	ts, ace	butolo)i_	-	-	-	-	-	-	***	2000	(00.0)	50
	-	-		-	-	_	-	-	-	-	-	-	-	358
_, clonidine _	-			_	-	810			-	-	466	40.0	168,	638, 670
_, guanabenz	_					-	-	-	~		_		_	638
_, labetolol _	_	-						_		_	_	-	407.	677, 685
_, metoprolol/hy	droch	loroth	iazide	comb	inatio	n							,	371
_, oxprenolol/cyc							_	-	_		-	_	-	559
_, penbutolol	Topen	critery	uc con	LOHILL	1OIL	-	-		-	-	-	-	-	267
	mida	annatai	nation	-		-	-	-	-			-	102	
_, pindolol/clopa					4-9	_		_	-	AMIN	-	-	193,	342, 552
		-		-	****	-	-	Brail	0.00	_	****	Back	-	528
_, propranolol					-	-		-	-	100	non	-	-	207
_, spironolactone	althi	azide	combi	nation	1 _	_	_	_	-		-		-	136
_, xipamide _	_	_	_			_	_	_	-	-	_	-	-	416, 523
Arthritis, rheuma	toid.	role of	fkinin	syster	11			_	_	no.	_	_	-	314
,, treatment wi									-	_	_			589, 598
, , fenbufen	masp	22 222		-	-		-		-	-	-	_	_	263
ibunes for	-		-	-	-	-		-	-	-	-	-	-	148
_, _, ibuprofen	-	10.00	-	-	-		-	-	-	-	Above:	-	1.40	
_, _, indomethaci					40.00				-	-	_	_	148,	263, 287
_, _, indoprofen	-	-		_	-	-	-	-	-	-	dest	-	-	598
_, _, ketoprofen	_	-	_	-	_	_	_	_		Acres .	ann.	-	-	423
_, _, magnesium	lithio	salicyl	ate		-		-	-	_		-	_	-	589
_, _, piroxicam		_		-		-								148
_, _, protacine	-				-				-	-	-			287
Aspirin, in low ba	ock no	in co	mnare	dwith	othe	ranal	macice	-	1000	-	-	-	-	540
								-	design		-	-	-	598
_, in rheumatoid						profe	1	-	-	-	-			
_, _, _, magnesiur	n dith	iosali	cylate				T		400	-	-	-	-	589
Asthma, treatmen	nt with	h cien	butero	l com	pared	with s	salbuta	amol	-	_	****	_	-	237
_, _, reproterol	***		_		_	_	-	_	_	-	_	_	-	365
Azatadine malea	te, effe	ect on	drivin	g perfe	ormai	nce		-	_	0.00	-	400	400	62
Benfluorex, use w	ith ar	ticoas	gulant	s in ca	rdiac	condi	tions				-			478
Benserazide, com								_	_	_				1
								otoco	ne but	rate		400	440	322
Betamethasone v		c, m u	Cilliai	1115, 00	unpai	cu wii			ne out		-	-		489
Biochemical rese			- III				-	-	****	-	-	4940	72	
Blood flow, effect					-	-	-	-	-		4000	-	13,	255, 518
_ viscosity, effect							444	-	_	man		_	-	271
Brain failure, chr	onic,	use of	pirace	tam	Acres		-		_		-	_	-	351
Bronchitis, treatr	nent v	vith er	ythroi	nycin	_	_	-	_	-	_	_	_	_	111
Bronchodilating	agents	s, clen	butero							_	_	_	-	237, 449
_, fenoterol _		-,												183
	_	_				-	-	_	-	-	-	-	-	365
, reproterol	_		_		-		-		-		10/10	-	_	183
_, rimiterol _	_	-	-		-		-	-		-	***	-	-	
_, salbutamol	_		-	****	-		90.00	-		-	-	-	_	237
_, terbutaline		-	-	-	-				-	-	_	1000	-	449
Butorphanol, in p	ost-o	perati	ve pai	n, com	pare	d with	codeii	ne	-	-	_	deside	_	178
Candicidin, com	bined	with :	5-fluor	ocyto	sine.	in vul	vovagi	nal ca	andidia	sis, c	ompa	ared	with	
clotrimazole				2	x					,				88
Cefaclor, in respi	rators	infoc	tion o	omna	rod w	ith am	micilli	17		_		-	_	564
		HITCU	tion, c	ompa	ICU W	rell cill	Pienn	II II was	_		-		-	569
_, _, _ amoxycillin			in the		-	inn F	_	_	-	-		(800)	_	
Cefamandole, tis							-		_			-		244
Cefuroxime, in lo					n_	-	-	_	_	-			_	466
, in post-operati	ve che	est infe	ection	_	_	-	-	_		-	10	_	-	209
_, levels in bronch				_	marin.	200	-	_	-	-	_	_		649
_, prevention of v								-	-		_	_	_	404
and gentamicin	in pa	tients	with r	educe	d rens	al func	ction							398
Cephaloridine, in	curpi	calwa	und i	fectio	n nre	ventio	n	-	-	_	-	-		204
			ranu II	Meetil	" bre	-611110	the.	-	-	-	200		_	564, 569
Cephalosporins,	ceraci	OI.	-	-	=	77	-	-	-	-	-	-		244

														P	age
Cephalosporins,	cefur	ovime									209	398,	404		_
_, cephaloridine	cciui	OAIIIIC	3000	-	-							-	707,		204
, cephazolin	_						_			_	-		1000	44,	
_, cephradine	- 1						_	-	_	-			_	386,	
Cephazolin, tissu _, prophylactic us						-	_	4	-	nine.	-	_	-		44 658
Cephradine, tissu						-	_		_	_	_		-		585
_, in urinary tract					-	_	_	-				_	_		386
Cerebrovascular	disor	ders, t	reatme	ent wi	th pen	toxify	lline		-			_	73,	255,	
Chlordiazepoxide Cholesterol, effec	e/am	itriptyl	line co	mbina	ation,	in dep	ressio	n_	-		****	***	-		573
Cholesterol, effec			nioron	niazio	e on R	eveis i	n nype	rtens	ives	-	_	-	_		24 249
Chlormethiazole.	in cl	hronic	alcoho	olism,	effect	on go	nadoti	rophi	ns and	testos	teroi	ne_	_		213
Chlormezanone,	in an	xiety-r	related	inson	nnia	_	***	-	-	_			400		259
, in rheumatic sl	eep d	lisorde	rs	-	-	-	-	-	4	-			-		217
Ciramadol, in ch	ronic	pain		-	-	-	-	-11	_	-	-		_		475
Clenbuterol, in as _, in asthma, con Clobazam, in any	irway	ys obst	ruction	n, con	ipareo	with	terbut	aline	No.	energy (_	-		449 237
Clobazam, in any	iety	comp	saibui	ith di	- azenar	-	_	-	-	-		-	-		593
Clobetasone buty	rate.	in der	matiti	s. con	pared	with	hetam	ethas	one va	lerate			-		322
_, in eczema, con											-	-	_		165
Clonidine, in hyp										No.	_	_		168,	
,, compared w	ith gu	uanabe	enz	_	_	_	_	_	_	_	-	-	-		638
Clopamide/pindo					perten	sion	****		-	-	_	\rightarrow	-	193,	
, effects on exc					ncie c	-	rod u	ith o	andici	din/5	fluor		cino		552
Clotrimazole, in combination	vui	vovagi	nai ca	Haidi	4515,	ompa	iled w	un c	andici	um/3-	Huor	ocyte	Sine		88
Codeine in nost-	oper	ative n	ain. co	mpar	ed wit	h but	orphai	lol	-	-		-	-		178
Colic, acute rena	l, ana	algesic	effect o	of dez	ocine	_	_	_	_		-	_			472
Communes, c	re ceres)	PARCOTTE	empob:	TO POTE	PATTORNA	563	200	-		~~	_	_			249
Co-trimoxazole,	comp	pared v	with ce	phrad	line in	urina	ry trac	t infe	ctions		-	_	-		386
Cyclopenthiazide	e/oxp	renoic	ol comi	oinati	on, in	nyper	tensio	n_	-	Promit .	-	-	-		559
Depression, treat	men	t with :	aminer	ntine									03	101,	107
_, _ amitriptyline										-	-	_	20,	93,	
_, _ amitriptyline	/chlo	ordiaze	poxide	com	binatio	on	_	_	_		-	_			573
_, _ amoxapine c						-		_	_	_	-	_			338
_, _ maprotiline		-		***	-	-	-	-	-	-	-	***	-	107,	
		with h	- atomo	thoso	no vol	-	-	olobo	tocono	history	- to	MH-16	-		101 322
_, allergic, treatm							versus	CIODG	tasone	butyl	ate	-	-		380
Dermatological a							_	_	_	-	_	_	_	377,	
_, betamethason	e vale	erate			Agent .	-			_		-				322
_, clobetasone bu	ityra	te _		_	-		-	***	14100	_	_		_	165,	322
_, desoxymethase _, hydrocortisone	one	-	-	_		-		_	-	_	_	-	_		502
_, hydrocortison	e but	yrate	_	_	_		iele lesse		-	17 1.	-	-	-	165,	502
Desoxymethasor Dextropropexyp													ther		502
analgesics_	110110	parac	ctanio	COIII	omati	O11, 111	1000	rack j	Jani, C	ompa.	ica v	AILLI C	rifer		540
Dezocine, analge	sic el	ffect in	renal	colic	-	_	_	_	_	-	-0-	_	_		472
_, in cancer pain	-	_		_		-	1,000		-	-	_	-	_		634
Diabetes mellitus			withg	glipizi	de	-	_	_	_		-	_	****		8
_, _ glipizide and	insu		-	-		****			_	\rightarrow	***	-	_		325
_, metformin	inte	-	-	-	and the	100	page.	-	-		-	ener.	-		201
_, _ phenformin Diacetylrhein, in		oarthr	itis	10.0	-	-	-	4000		-	-	men.	-		201 548
Diazepam, in an				vith cl	obaza	m	-		-	_	-	-			593
Diflunisal, effect						-	_	_	_	_	-	_	_		510
_, in pain after C						mefe	namic	acid		_	-	-	_		630
, used post-oper	rative	ely	-	-		anne	_	_		-	-	-			154
Dipyrone, in pos										440	-	***	-		614
_, in post-operat	ive pa	ain, co	mpare	d With	petni	dine	-	-		-	-	-	-		624
Disopyramide, u	se in	pregn	ancv	-		_			****	****	-	-	-		70
Diuretics, althia				th spi	ronola	ctone	_			-	_		-		136
_, clopamide, con						-	_	-	-		-		193.	342,	552

														Page
Diuretics, cyclope			ombin	ed wit	th oxp	renol	ol	-		****	-	***	-	559
_, hydrochlorothi _, hydrochlorthia			ed wit	h met	oprol	ol		-	-	-	_	-	-	24 371
_, muzolimine		-			_	Seed.		Seed.	-	_	-	-		431
_, xipamide _	-	- la hor	-	-	-	-	-	-	-	-	no-	-	-	416, 523
Domperidone, in Doxycycline, in go						th niv	-	cillin	=	***		-	-	577 513
_, in respiratory in								CIIIII		-	-	***	-	393
Drug research, ro								_	-	_		-	-	488
												-	-	
Eczema, treatmen	t with	clobe	tasone	buty	rate	-	-	-	-	-		-	-	165
_, _, hydrocortiso _, _, desoxymetha	sone	tyrate	iem	-	N-W	-	-		-	-	-	-	-	165, 502 502
Erythrocyte flexib	ility.	effects	of per	toxif	vlline	-	-			-	-	-	-	255, 518
Erythromycin stea						_		_	_		-		_	111
_, plasma and sali					_	-		_	mar.		_	-	***	118
Etomidate, in mir	or op	erativ	e proc	edure	s, con	pare	d with	thiope	entone	sod	ium	_	_	30
Eanhufan in show	manta	id anth	mitio /		wad u	dela im	damai	thooim						262
Fenbufen, in rheu Fenoterol, in reve										-	-	-	-	263 183
Feprazone, in acu										-	-	-	2000	445
Flunisolide, in all				. *****	pitett	,1044	aLOHE	-	-	-	-	-	-	14
5-Fluorocytosine.				andic	idin, i	n vul	vovagi	inal ca	ndidia	asis,	compar	red	with	
clotrimazole	_	-	-	-	-	-	_		-	-	-	(1842)		88
Canital disasses	Famala	trans	mant	with	inon	nioilli	2002	narad	with d	lavu	avalina			513
Genital diseases, f Gentamicin/cefur												-	-	398
Gentamicin, com										-	-	-	-	663
Glipizide, in diab					501100	13 3 3 3 1	CITILO I	1110001	7113				-	8
_, _, associated wi			_	_	_	_	_		_		_		_	325
Gout, treatment v	vith fe	prazo	ne con	npare	d with	pher	ylbuta	azone	-	-	-	_	_	445
Guanabenz, in hy	perter	nsion,	comp	ared v	vith cl	onidi	ne	-	-	-	-		-	638
Hay fever, treatm	ont wi	th flu	nicolid	0										8
_, oxatomide	CIII WI	idi ildi	1150110		_		-		-	-	-	-	_	380
Herpes genitalis,	treatn	ent w	ith po	vidon	e-iodi	ne	_		_	_	_	_	_	175
Hiatus hernia, tre							ntacid	comb	natio	n	_	_		645
_, _ hydrotalcite	_		_	_	_	_	-	-	_	-	_	-	-	85
Hydrochlorothia		in hyp	perten:	sion,	effect	s on	plasm	a trig	lyceric	de, o	choleste	rol	and	
HDL-cholester		- 1	-	-	-	-	-	-		-	-	1000	-	24
,, combined wi	th me	toproi	01	- 000	-	- ith	olohot	-	harten	-	-	-	-	371 165
Hydrocortisone b	ma c	omnai	ed wit	h des	ovvm	thace	cionei	asone	butyi	ate	-	-	-	502
Hydrotalcite, in h						illast	JIIC	-	-	-	-	-	_	85
Hypertension, tre							_				_		_	50
_, _, alprenolol	-		-	_	1000	-	_	_	-	_	_	_	_	358
_, _, clonidine		-	-	-	-	***	_	_	_	-	-	-	168,	638, 670
_, _, guanabenz	-	-	-	-	_	_	-	-	-	-	-	-	_	638
_, _, hydrochloro	thiazio	de	-	None,	-	No.		-	-	-	-	-	405	24
_, _, labetolol	-,	1.7		-	1.1	-	-	-	-	-	-	-	407,	677, 685
_, _, metoprolol/h	iyaroo	chioro	thiazid	de cor	nbina	tion	_	-	1000	-	-	-	-	371 559
_, _, oxprenolol/c	yclop	entma	zide co	JIIIUII	iation	-	-	-	-			-		267
_, _, penbutolol _, _, pindolol/cloj	namid	ecom	hinati	on	-	-	-	-		-	-	-	193	342, 552
_, _, primidolol		-			dare.	***	-	-	-	-	-		1229	528
_, _, propranolol	ter.	_	_	-	-	_	_	-	-	-	_		_	207
_, _, spironolacto	ne/alt	hiazid	e com	binati	on	_	-	_	_	_	_	_	-	136
_, _, xipamide	_	_	-	_	_		_	***	-	-	***	_	_	416, 523
Hypnotics/sedati			ite	-		-	No.	-	-	-	-	-	-	30
_, thiopentone so		-	-	-	-	-	-	-	-	-	-	-	-	30
_, chlormezanone		-lin'	id.	****	-	Note	-	-	-	-	-	-	-	217, 259
Hypoglycaemic a	gents,	glipiz	ande	-	-	-	-	-		-	-	-	-	8, 325 201
_, metformin _, phenformin	-	***	-		-	-	-	Mari.	***	-	-	-	-	201
, phemornin	100	-	-	-	No.		-	-	-	1000	-	-	-	201
Ibuprofen, in rhe								am an	d indo	met	hacin	_	_	148
Imipramine, in de								_		_		_	_	338

								Page
Indomethacin in low back pain compared with oth	or anal	gacies						540
Indomethacin, in low back pain, compared with other, in rheumatoid arthritis, compared with fenbusen			_	-	-	_	_	263
		-	-	_	-	_	-	148
_, _, _, piroxicam and ibuprofen	10100	~996		-	-	-	-	287
Indoprofes in actorarthritis	0-0	-			-	Mary .		124
Indoprofen, in osteoarthritis, in rheumatoid arthritis, compared with aspirin Irritable bowel syndrome, treatment with domperide trimebutine compared with mebeverine		4*****	-	_	_	_	-	598
Leritable howel condrame treatment with downeride	one	-		_		-	_	577
trimebuting compared with mahavering	DITE	_	_	-	-	-	_	437
_, _ trinicoutine compared with meseverine _		_	_			_	_	451
Ketoprofen, in rheumatic and osteoarthritic disorde	rs_	-	-	_	_		807	423
Kinin system, role in rheumatoid inflammation _			-	_	_	_	_	314
Labetalol, in hypertension	-	-	-	gering	-	_	407,	677, 685
Leishmaniasis, cutaneous, treatment with stibogluco	onate so	odium	_		*	99.0	-	280
Levamisole, in upper respiratory infections		-	non.	winds:	-	_	-	142
Levamisole, in upper respiratory infections Levodopa, combined with benserazide, in parkinson Lipoproteins, HDL, effect of hydrochlorothiazide,, changes during oral contraception Lorazepam, inter-trial differences, use in cardiac bypass surgery, compared with paper	ism	_	-			-	-	1
Lipoproteins, HDL, effect of hydrochlorothiazide	No.			-	_	_	-	24
_, _, changes during oral contraception		-	_	_	0.000	-	-	249
Lorazepam, inter-trial differences	***	-		-		_	_	20
_, use in cardiac bypass surgery, compared with paper	averetu	ım		_	_		****	303
Magnesium dithiosalicylate, in rheumatoid arthritis.	, comp	ared w	ith as	pirin				589
Maprotiline, in depression, compared with aminepti	ne	-					_	107
,, amitriptyline								534
Meheverine, in irritable colon syndrome, compared	with tr	imebu	tine			_		437
Mecillinam, in severe bacterial infections _ melenamic acid, in low back pain, compared with or _ in pain after Colles' fracture, compared with diffurment in diabetes mellitus Metoprolol/hydrochlorothiazide combination, in hy								221
Mefenamic acid in low back pain compared with or	theran	algesia	20	-	_		_	540
in pain after Colles' fracture compared with diffu	nical	aigesi	63	_	Asses	No.	-	630
Motformin in dishetee mellitus	111541	-				-	_	201
Metrornin, in diabetes meintus			_	_		elever.	-	371
Metoproioi/nydrochiorothiazide combination, in ny	perten	SION	-		****	Mary .		
Mianserin, sieep-endocrine profile	-	_	-			-		456
Moniliasis, vulvovaginal, treatment with clotrimaz	ole ver	sus 5-	Huoro	cytosi	ne/car	ndic	cidin	0.0
combination	-	-	-	-	-	_	-	88
Muzolimine, pharmacokinetics in severe cardiac fail	lure pa	tients	_	-	***			431
AT 1 1 00 . 0 1 1								
Nandrolone, effects on rarefying bone tissue	-		_	60%	-	_	4-0-	606
Naproxen sodium, treatment of non-articular rheum	natic di	sorde	rs .	-	_	-	_	229
Neuroses, anxiety, treatment with chlormezanone	0.00	-	Man			_		259
_, _, _ clobazam compared with diazepam _	_		_	-	_	-	-	593
lorazenam								20, 303
Nifedipine, effect on glucose tolerance and insulin se	ecretion	11			_	_	-	690
Nitrofurantoin/sulphadiazine combination, in acute	urina	ry infe	ctions	_	-	_	_	481
Osteoarthrosis, treatment with diacetylrhein	-	nie.	-	-	100	2000	-	548
_, _, ketoprofen		_	_	-	_	-		423
indoprofen								124, 287
protacine compared with indomethacin								287
Osteonorosis effects of nandrolone	A-40,	pass.	_	_	100	***	_	606
osteobardinosis, feathers with diaceyment, ketoprofen, indoprofen	-	-	-	_	.000	Audit	_	380
Overendal/avalenenthiazide combination in hyper	tonsion	-	-80	-	-	-	-	559
Oxprenoior/cyclopentmazine comomation, in hyper	telisioi	1	-		-	-	-	333
Pain concer treatment with siremedal								475
Pain, cancer, treatment with ciramadol			0.00	-	_		-	634
	ad mist	-	-	-	Acres	_		630
_, Colles' fracture, treatment with diflunisal compar	ea will	i mere	namic	acid	-	desir	-	
, leg ulceration, treatment with thymoxamine _, low back, comparison of analgesics			10,000	_	-	_	-	500
_, low back, comparison of analgesics	-		-	-	_	_	-	540
_, post-episiotomy, treatment with dipyrone compan					_	-	-	614
_, post-operative, treatment with butorphanol comp	ared w	ith co	deine	_			1-10	178
_, _, _ diflunisal		_	_	-	-		-	154
_, _, _ dipyrone compared with aspirin	-	_	_			-	_	619
_, _ dipyrone compared with pethidine	(400)	mon.	-	-	-	-		624
_, severe renal colic, treatment with dezocine	_	879	-	_		_	-	472
_ tennis elbow, treatment with triamcinolone acetor	nide	_	_		***			507
Paracetamol in low back pain compared with other	ranalo	esics	_		_		-	540
-, -, dipyrone compared with aspirin -, dipyrone compared with pethidine -, severe renal colic, treatment with dezocine -, tennis elbow, treatment with triamcinolone acetor Paracetamol, in low back pain, compared with other -, in post-episiotomy pain, compared with dipyrone	with E	-0.00	_		_	-	200	614
Parenteral nutrition, use of a high nitrogen source as	mino	cid sol	ution		_		81/10	274
Parkinsonism, treatment with levodopa/benserazide					-	-	500	1
a management with the action of the control of the	UIIIIU.	INITESTAL IN		_	000	4000	-	

												Page
Penbutolol, in Rayn	aud's phenor	nenom,	vasoc	onstri	ctor eí	fects	_			_	-	267
Pentoxifylline, in cer			ers	-		***	-	-	-	no.	-	73
, effect on erythroc			-		-	-	-	-	-	-	-	255, 518
Peptic ulcer, treatme				h din	_	-	-	-	-		-	85 624
Pethidine, in post-or Phenformin, in diab						-	-	-	-	-	-	201
Phenylbutazone, in								_			***	445
_, in low back pain,						-	-	-	_	_	_	540
Pimozide, in schizop	ohrenia _			_		-		-	_	_	-	35, 331
Pindolol/clopamide			ertensi	on	-	-		-	-	-140	-	193, 342
_, _, effects on exerc					-	Asset	-	-	-	-	-	552
Piracetam, in chroni Piroxicam, in rheum	ic brain failur	e _	arod v	ith ih	-	en and	lindo	metha	cin	-	-	351 148
Pivampicillin, in ger	ital infection	s, comp	ared w	ith de	XVCVC	cline	i indo	metna	CIII	-	-	513
Povidone-iodine, in	herpes genita	lis_		_	_	_	-	_	-			175
Primidolol, in hyper		-		_		_	No.		-	_	_	528
Propranolol, advers	e reaction in l	nyperter	sive d	ialysi	s patie	ents	med.	-		-	-	207
Protacine, bioavaila			-	-	-		-	-	-	-	_	299
_, in rheumatoid art	hritis and ost	eoarthri	tis, co	mpar	ed with	h indo	metha	ncin	-	-	-	287
Raynaud's phenome	enon, effects of	of penbu	tolol	-	-	_	-	_	_		Part	267
_, after treatment wi	th propranol	ol _	_	_	***	-	-	-	_	_	-	207
Reproterol, in asthn				-	-			-			_	365
Respiratory tract inf	fections, lowe	r, treatn	nent w	ith ce	factor	comp	ared v	vith ai	noxyc	illin	-	569
_, _, _ cefaclor comp	pared with am	picillin	-	-	-		-	-	-	-	-	564 209, 466
_, _, _ cefuroxime _	dovveveline		d with		vvcilli:	-	-	_	-	-		393
_, _, treatment with _, upper, prevention	with levamis	ole	d with	anio	AyCIIII.	11	-			-	-	142
Rheumatic disorder			ment	with k	etopr	ofen	-	_				423
_, _, _ naproxen sod		_	_	_	- Par	_	_					229
Rimiterol, in airway	s obstruction	, compa	red wi	th fen	otero	_		_	_	-	_	183
Salbutamol, in asthr	na comparec	with ch	enhute	erol								237
Schizophrenia, use o		1 WILLIE	ciioun	101	-			_	-			35, 331
Sisomicin, in serious		ections.	compa	red w	ith ge	ntami	cin	_		_		663
Sleep, effects of mian		-	_	_	_	_	-			_		456
_, _ vincamine _	Ann and	_	_	_	_	-	-		-	_	_	653
Sleep disorders, trea	tment with cl	nlormez	anone		_	-	-	-	-	444	-	217, 259
Spironolactone/alth	iazide combi	nation, i	n hyp	ertens	ion	-	-	_	-	-	-	136
'Steritex vacu-drain'	, in major sui	rgery	-				-	-	-	-	-	160 280
Stibogluconate sodi Sulphadiazine/nitro						vinfor	tion	-	-	-	-	401
Sulphinpyrazone, ef				icute	uiiiai	ymmed	, tion	_		-		271
Surgical wound infe				roxim	e_	_	_			_	_	206, 404
_, _cephaloridine _		_	-	-	_	-	_	_	_	_	_	204
_, use of 'Steritex va		tem	404	-	_	-	-	_	_	_	_	160
Tennis elbow, treatr	nent with tria	meinole	ne ac	etonid	6							507
Terbutaline, in airw	avs obstruction	on, com	pared	with	lenbu	terol	_					449
Thiopentone sodiun	n, induction i	n minor	opera	tive p	rocedi	ures, c	ompa	red wi	th eto	midate	e_	30
Thymoxamine, in is				_	-	-	-	_	-	-	-	500
Tranquillizing agent	ts, clobazam	drain.		-	_	_	-	_	_	_	-	593
_, diazepam		-	-	-	-	-	-	-	-	-	-	593
_, lorazepam			-	-	-	-		-	-	-	-	20, 303
Triamcinolone acete				lovala	- h	-	inac	-	-	-	-	24
Triglycerides, effect Trimebutine, in irrit								-	-	-	-	437
Trimipramine, in de						HEDEVE	11110	-	_	-	_	101
				p					-			
Ulcers, leg, treatmen				-000	-	-	***	-	***	-	-	500 309
_, _, _ xanthinol nice Urinary tract infecti		on with	cenha	zolin.	April .	-	-	-	-	-	-	658
_, treatment with ce						-		-	-	-		398
_, _ cephradine com							_	_	_			386
_, _ nitrofurantoin/s	sulphadiazine	combin	ation		_	_	_			-		481
												653
Vincamine, effect or				-	-	-	-	-	-	-		
Xanthinol nicotinat			-	-	-	-	-	-	-	-	-	309
Xipamide, in hypert	tension	-	-	(male)		-	-	400	-		1130	416, 523

Supplements to Volume 6

Supplement No. 1. Fenfluramine and the treatment of obesity	. page
	. page
General and comparative pharmacology of fenfluramine. J. Duhault, L. Beregi and R. du Boistesselin	3
Biochemical pharmacology of the anorectic drug fenfluramine: a review. S. Garattini, S. Caccia, T. Mennini, R. Samanin, S. Consolo and H. Ladinsky	15
Fenfluramine and other serotoninergic drugs depress food intake and carbohydrate consumption while sparing protein consumption. Judith J. Wurtman and Richard J. Wurtman	28
Structural analysis of the actions of amphetamine and fenfluramine on food intake and feeding behaviour in animals and in man. J. E. Blundell, C. J. Latham, Esmeralda Moniz, R. A. McArthur and P. J. Rogers	34
Lack of morphological changes in the neurons of the B-9 group in rats treated with fenfluramine. C. Sotelo and A. Zamora	55
Fenfluramine and its effects on the sympathetic nervous system in man. C. Raymond Lake, Michael D. Coleman, Michael G. Ziegler and Dennis L. Murphy	63
The importance of stress in assessing the effects of anorectic drugs. Seymour A. Antelman, Anthony R. Caggiula, Alan J. Eichler and Ronald R. Lucik	73
The effects of fenfluramine on appetite for palatable food in humans. Orland W. Wooley, Susan C. Wooley and J. Caroline Lee	83
The mode of action of fenfluramine and its derivatives and their effects on glycerolipid metabolism. David N. Brindley, R. Graham Sturton, P. Haydn Pritchard, June Cooling and Susan L. Burdlit	91
Peripheral mechanism of action of fenfluramine, Paul Turner	101
A comparative study of the pharmacokinetics of fenfluramine, ethylamphetamine,	
diethylpropion and their metabolites. Arnold H. Beckett	107
Addiction liability of fenfluramine. Uriel Estrada	118
Investigations of abuse potential of anorectic drugs. K. Gunnar Götestam	125
Studies on central functional equivalence. III: classification of several psychomotor stimu-	
lants and anorectic agents. William Slikker, Jr., and Keith F. Killam, Jr	135
Abuse of anorectic drugs. Raghu Gaind and Sarla Verma	149
Drug dependence liability of anorectic drugs: a clinical viewpoint, with particular	153
reference to fenfluramine. P. H. Connell. Fenfluramine plasma concentrations after administration of a sustained-release capsule formulation and rapid-release tablets. D. B. Campbell, Y. Hopkins, R. Richards and	155
D. Taylor Effect of prolonged-action fenfluramine on weight and blood lipids in obese patients.	160
Rudolf E. Noble _ A double-blind comparison of fenfluramine and dextro-amphetamine on feeding behaviour	169 180
in man. Mary Kyriakedes and Trevor Silverstone Studies on fenfluramine as an anti-obesity agent. P. G. Preston, M. J. Ford and J. F. Munro Treatment of obesity with fenfluramine: a double-blind trial. Jean Vague and Martine	188
Tramoni _ The possible mode of action of fenfluramine in the treatment of diabetes; a review.	194
C. H. Bowker	203
Metabolic effects of fenfluramine in animals and human volunteers. H. Förster and E. Koch Metabolic effects and anti-obesity action of fenfluramine in prolonged-acting form.	207
R, Ranquin and H. M. Brems	219
The effect of fenfluramine on obese, maturity-onset diabetic patients. John K. Wales	226
Analysis of the metabolic activity of prolonged-acting fenfluramine in clinical practice. B. Riveline	236
The influence of fenfluramine on oral glucose tolerance tests, plasma sugar and insulin levels in newly diagnosed late-onset diabetic patients. J. W. H. Doar, M. E. Thompson,	
C. E. Wilde and P. F. J. Sewell	247
A behavioural and pharmacological treatment for obesity with a 3-year follow-up.	
K. Gunnar Götestam	255
Supplement No. 2. Some epidemiological, social and therapeutic aspects of rheumatology Supplement No. 2.	. page
Arthritis as a world-wide problem. F. Dudley Hart	3
Some aspects of present day preventive rheumatology. M. Assunção Teixeira, João	
Salgueiro and J. Valença Rodrigues	9
Epidemiological aspects of rheumatology. João Figueirinhas Septic arthritis in Northern Nigeria. R. D. Sturrock	15 21

Sum	pl. page
Back pain: its problems and treatment. George D. Kersley	27
Emotional factors in arthritis. Brenda M. Rutter	33
Patient Counseiling—its impact and importance in rheumatology. Roaney Grahame	42
Social effects of rheumatism on the family. Pirkko Kiviniemi.	47
Experimental and clinical pharmacology of fentiazac, a new, non-steroidal anti-	
inflammatory agent. Emilio Marmo	53
Fentiazac in rheumatoid arthritis: a multicentre study. Aloysio Fellet	64
Efficacy and tolerability of fentiazac in rheumatoid arthritis: double-blind study versus	
indomethacin. Gabor Katona and Augusto Bondani	71
Fentiazac in the treatment of acute tendinitis and acute bursitis: a double-blind compari-	
son with oxyphenbutazone. A. P. Mathias Filho, B. Klein, C. V. Nunes, R. A. Carneiro,	
R. Lederman and W. Bianchi	79
Double-blind trial comparing fentiazac with phenylbutazone in patients with tendinitis.	
L. Wielandts and J. Dequeker	85
A double-blind comparison of fentiazac and phenylbutazone in the treatment of acute	05
tendinitis and bursitis. Ellen M. Buerklin and Ian M. Ballard	90
Fentiazac in the treatment of some rheumatic disorders. M. Assunção Teixeira, A. Pereira	20
da Silva, Isabel Lourenço and M. Luisa Teixeira	97
au Sirve, isuoti Lourenço una ira. Emiste reixenta	21
Supplement No. 3. Uses and abuses of antimicrobials	
Sup	pl. page
Antibiotics in non-specific genital infections. G. L. Ridgway	3
Antibiotics in dentistry. James Wallace Legionnaires' disease: a review. D. C. Shanson Respiratory tract infections in childhood. R. Dinwiddie Antimicrobials in 1978: a review of current opinion. J. McC. Murdoch Problems of thymine-dependent bacteria in clinical practice. R. Fraser Williams	13
Legionnaires' disease; a review. D. C. Shanson	22
Respiratory tract infections in childhood. R. Dinwiddie	20
Antimicrobials in 1978: a review of current opinion. J. McC. Murdoch	20
Antimicrobials in 1978: a review of current opinion. J. McC. Murdoch Problems of thymine-dependent bacteria in clinical practice. R. Fraser Williams	43
Campylobacter enteritis, I. R. Ferguson	54
Campylooacter enteritis. I. R. Perguson	61
Antibiotics in the treatment and prevention of pertussis. H. P. Lambert	01
Supplement No. 4 Post outfulling in the treatment of micropinculatory disorders	
	pl. page
Sup Introduction. S. G. Kobaladze	pl. page
Sup Introduction, S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with	3
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease, S. G. Kobaladze and G. S. Schonia	
Sup Introduction. S. G. Kobaladze_ Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and	3
Sup Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze	3
Introduction. S. G. Kobaladze. Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland	3 5 12
Sup Introduction. S. G. Kobaladze_ Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miller	3 5 12
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with	3 5 12
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D.	3 5 12 15
Introduction. S. G. Kobaladze_ Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze	3 5 12 15
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi.	3 5 12 15
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi.	3 5 12 15
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvido-	3 5 12 15
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani	3 5 12 15
Introduction. S. G. Kobaladze. Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Sliencevic and M. Devecerski	3 5 12 15 25
Introduction. S. G. Kobaladze. Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Sliencevic and M. Devecerski	3 5 12 15 25
Introduction. S. G. Kobaladze. Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Sliencevic and M. Devecerski	3 5 12 15 25 30 37
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzt-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković	3 5 12 15 25 30 37
Introduction. S. G. Kobaladze. Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miiller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitič	3 5 12 15 25 30 37
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić	3 5 12 15 25 30 37 43
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miiller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, L.J. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation, F. Lehrach and HG. Grigoleit	3 5 12 15 25 30 37 43
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miiller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, L.J. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation, F. Lehrach and HG. Grigoleit	3 5 12 15 25 30 37
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegut-schwili, V. A. Kipiani, T. G. Natadze, T. G. Petriaschwili and J. V.	3 5 12 15 25 30 37 43
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miiller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, L.J. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation, F. Lehrach and HG. Grigoleit	3 5 12 15 25 30 37 43 49
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegut-schwili, V. A. Kipiani, T. G. Natadze, T. G. Petriaschwili and J. V.	3 5 12 15 25 30 37 43 49
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegutschukla de fefect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegutschukla de fefect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegutschukla de fefect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegutschukla de fefect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegutschukla de fefect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegutschukla de fefect of pentoxifylline on regional vascular systems. N. J. Refracchwili and J. V. Tschikvadze	3 5 12 15 25 30 37 43 49
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Geguischadze, A. P. Gelaschwili, V. A. Kipiani, T. G. Natadze, T. G. Petriaschwili and J. V. Tschikvadze	3 5 12 15 25 30 37 43 49
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Geguischadze, A. P. Gelaschwili, V. A. Kipiani, T. G. Natadze, T. G. Petriaschwili and J. V. Tschikvadze	3 5 12 15 25 30 37 43 49 57 opl. page
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Müller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, Lj. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Gegut-schadze, A. P. Gelaschwili, V. A. Kipiani, T. G. Natadze, T. G. Petriaschwili and J. V. Tschikvadze	3 5 12 15 25 30 37 43 49 57 opl. page 3
Introduction. S. G. Kobaladze Pentoxifylline and some physico-chemical aspects of haemorheology in patients with ischaemic heart disease. S. G. Kobaladze and G. S. Schonia The use of pentoxifylline in the treatment of ischaemic heart disease. S. G. Kobaladze and I. V. Tschikvadze Cerebrovascular insufficiency: its pathophysiology and therapeutic management. Roland Miiller The cerebral haemodynamics and therapeutic efficacy of pentoxifylline in patients with cerebral ischaemia. V. M. Gabaschwili, S. G. Kobaladze, R. R. Schakaraschwili, M. D. Virsaladze, Sch. P. Petriaschwili and I. V. Tschikvadze Pentoxifylline in the treatment of pathological vascular changes in the fundus oculi. T. A. Schatilova, T. A. Aleksidze, M. A. Kvaliaschwili, D. M. Kandelaki, E. G. Mschvidobadze, T. N. Kalandadze and I. V. Oniani The use of pentoxifylline in insulin-dependent diabetics with late complications. D. Slijepcevic and M. Devecerski Experiences with pentoxifylline in the treatment of peripheral vascular disease. D. Mihajlović, L.J. Hadzi-Pesić, V. Marković, B. Lović, D. Cirić, Z. Marković, A. Stanković and V. Mitić The flow properties of whole blood under physiological and pathological conditions: microrheological investigation. F. Lehrach and HG. Grigoleit The effect of pentoxifylline on regional vascular systems. N. J. Andreeva, M. D. Geguischadze, A. P. Gelaschwili, V. A. Kipiani, T. G. Natadze, T. G. Petriaschwili and J. V. Tschikvadze Supplement No. 5. Physical and psychological aspects of the premenstrual syndrome	3 5 12 15 25 30 37 43 49 57 opl. page

Count on	0.00
Suppl. pr	age
Endocrine and other biochemical factors in the aetiology of the premenstrual syndrome. M. G. Brush	19
Recent research on the treatment of premenstrual syndrome. P. F. H. Giles	28 35
Premenstrual syndrome in general practice. Barbara R. Jacobs Clinical trials in the premenstrual syndrome. J. B. Day	40
The clinician's view of patients with premenstrual syndrome. R. W. Taylor and C. E. James	46
Supplement No. 6. International theophylline symposium Suppl. pa	200
	3
The pharmacokinetics of theophylline. <i>Ian W. French and C. A. Mildon</i> — Chemical and biopharmaceutical aspects of theophylline and its derivatives. <i>J. Zuidema and F. W. H. M. Merkus</i> —	14
Why measure plasma theophylline concentrations? Denis G. McDevitt, R. Kevin Elwood and Clive J. Russell	26
The mode of action of the ophylline, R. Pauwels	35
Clinical trial of a new, slow-release theophylline preparation ('Nuelin' SR). N. Svedmyr, T. Mellstrand and K. Svedmyr	40
The question of dosage: clinical studies of high and low dosage theophylline in asthmatic	
children. Roger M. Katz, Gary S. Rachelefsky and Sheldon C. Siegel _ Microcrystalline theophylline: the relation between oral dose, saliva levels, and peak	45
expiratory flow rates in asthma. G. Anderson, A. G. Jariwalla, E. Hicks and M. Al-Zaibak	51
General Discussion, Chairman; Professor M. Van Der Straeten	59
Clinical and pharmacological observations on a new oral preparation of theophylline. Nils P. Boye, Tore Talseth and Jan E. Bredesen	63
Multi-dose comparative study of microcrystalline theophylline and choline theophyllinate. W. Christina Berg, J. H. G. Jonkman, K. de Vries and N. G. M. Orie	64
The absolute bioavailability of microcrystalline theophylline. J. H. G. Jonkman, W. Chr.	71
Berg, R. Schoenmaker, J. E. Greving, R. A. De Zeeuw and N. G. M. Orie Combined effects of theophylline beta ₂ -adrenoceptor stimulants in asthmatics. Nils	1 %
Svedmyr and Karin Svedmyr	77
The additive and/or synergistic effects of combined sympathomimetic and methylxanthine therapy, I. A. Campbell	85
Clinical studies of the relative potencies and the combined effects of theophylline and beta-	
adrenoceptor agonists. G. E. Marlin, N. Berend, M. R. Harris, B. J. S. Hartnett and J. Rutland	92
The role of oral theophylline in the management of childhood asthma. R. Dinwiddie and	
211111111111111111111111111111111111111	102
	110
Formulations and dosage requirements for theophylline in the treatment of asthma.	116
Miles Weinberger and Leslie Hendeles Clinical study of a sustained-release theophylline preparation in asthmatic ad. lts.	116
H. Lamont, M. Van Der Straeten, E. Moerman, M. Bogaert and P. Pauwels	132
Comparative systemic availability of rectal and oral preparations of microcrystalline theophylline. T. B. Tjandramaga, R. Verbesselt, A. Van Hecken and P. J. De Schepper	142
Simultaneous determination of the ophylline and its metabolites in urine. R. Verbesselt,	
T. B. Tjandramaga and P. J. De Schepper Theophylline therapy in asthmatic children: single-dose studies. Zack H. Haddad, Sanjiv	151
Verma and Vin Kalra	161
General Discussion. Chairman: Anne Tattersfield	171
Supplement No. 7. Mianserin in the treatment of depression Suppl. pc	398
Introduction. T. Vossenaar	3
Neurobiology of depression in relation to pharmacological-biochemical properties of	
antidepressants, N. Matussek Relative toxicity of amitriptyline, imipramine, maprotiline and mianserin in acute	5
experiments in rabbits. I. E. Hughes and Salwa Radwan	13
The effect of mianserin on sleep and cardiac function. S. Montgomery Echocardiographic study in volunteers taking mianserin and amitriptyline. H. A. Wester	23
and CP. Siegers	29
Cardiac effects of mianserin: results of clinical pharmacological investigations. H. Kopera_ The comparative safety of mianserin in overdose W. L. Shaw	36

Supp	l. page
Changes in clinical symptomatology and psychometric assessments in depressed patients during mianserin and combined amitriptyline/chlordiazepoxide therapy: a double-blind	
comparison. B. Saletu and J. Grünberger A double-blind comparative trial of mianserin and maprotiline in the treatment of	52
depression. M. C. Khan and K. Moslehuddin	63
A double-blind group comparative trial of mianserin and diazepam in depressed outpatients. W. Hamouz, R. M. Pinder and S. M. Stulemeijer	72
A double-blind controlled multi-centre study comparing mianserin and imipramine. C. B.	81
Pull, P. Pichot, M. C. Pull and J. F. Dreyfus A comparison of the efficacy and side-effects of mianserin and clomipramine in primary	01
depression: a double-blind randomized trial. R. De Buck Double-blind comparative trial of mianserin versus clomipramine. L. Blaha, R. M. Pinder	88
and S. M. Stulemeijer	99
Mianserin, in out-patients with depressive illness, in dosage up to 130 mg daily. H. Hopman A double-blind multi-centre trial comparing the efficacy and side-effects of mianserin and clomipramine in depressed in-patients and out-patients. R. M. Pinder, A. Blum, S. M. Stulemeijer, M. Barres, M. Molczadzki, A. Rigaud, J. Charbaut, L. Israel and Th. Kanmerer	107
Observations on mianserin in the treatment of obsessive neuroses. Martti O. Jaskari	128
Anticholinergic effects of mianserin. H. Kopera Effects of mianserin in depression in elderly patients. J. Fleischhauer	132 139
Mianserin and amitriptyline in elderly hospitalized patients with depressive illness: a	
double-blind trial. J. H. Kretschmar	144
Supplement No. 8. Erythromycin – today and tomorrow Supp	ol. page
Introduction.	3
A pharmacokinetic study of erythromycin in man. F. Lhoste, G. Houin, CJ. Soussy, J. Duval, M. Rapin and JP. Tillement Pharmacokinetics of erythromycin in healthy adults and in adults with respiratory	7
infections. C. Simon	17
Serum and tissue concentrations of erythromycin: a review, G. A. Dette_ Binding to human plama protein and drug interactions: an in vitro study with ¹⁴ C-labelled erythromycin base, JP. Tillement, H. Campos y Sansano, Ph. d'Athis and J. Prandotto_	23
General discussion on pharmacological studies	35
Direct microscopic observation of the effect of erythromycin on Staphylococcus aureus. G. Lebek	38
Efficacy of erythromycin lactobionate in acute exacerbations of chronic bronchitis. F.	42
Lemaire, D. Matamis, CJ. Soussy, F. Lhoste, J. Duval and M. Rapin Erythromycin in upper respiratory tract infections. C. Simon and S. Harhausen Erythromycin in chronic tonsillitis: qualitative and quantitative aspects of bacteriological	48
and electron microscopical results. H. Blenk, B. Blenk, G. Jahneke and K. Simm General discussion on bacteriological and clinical studies	54 60
Erythromycin and respiratory infections: three case reports. M. Kienitz	65
Current appraisal of the macrolides compared with other antibiotics and the main indications for their use. M. Armengaud	68
Mycoplasma pneumoniae infections in paediatrics and their treatment with erythromycin.	
G. Ruhrmann Respiratory infections due to Mycoplasma pneumoniae in the adult patient. J. Miguères	72
and A. Jover	73 77
Erythromycin in the treatment of asthma attacks of infectious origin, J. Brune Anti-infective chemotherapy in chronic bronchitis: the place of erythromycin, M. Rapin _	80
Rheumatic fever prophylaxis with erythromycin. D. Brunel	82
Current aspects of sexually transmitted diseases: the place of erythromycin in treatment. A. M. Siboulet	85
Erythromycin in chlamydial and mycoplasma genito-urinary infections: in vitro and in	91
vivo activity. H. Blenk. The use of erythromycin in the treatment of chlamydial urethro-adnexitis. A. Hoffstetter _	93
Genito-urinary infections due to chlamydiae: their current incidence, diagnosis and treatment. A. F. Siboulet	96
Mycoplasma and chlamydiae infections in the perinatal period. W. Toeller	99
Clinical importance of genital infections in women due to anaerobic bacteria, and the role of erythromycin. H. Werner and C. Krasemann	102
of erythromyclin. H. Werner and C. Arasemann	102

Supplement No. 9. Pfizer-Forum 1979 (Papers in N	orwegia	an and	Engl	ish)				
				,			Suppl.	page
Innledning: prazosin. (Introduction). Haakon Storn Primær hypertensjon og prazosin. (Primary hyperte Prazosin ('Peripress')—litteraturoversikt. (A revie	nsion an	nd pra					- Per	3 5
Fauchald	_	-	_		_	_	-	12
Prazosin ('Peripress') som alternativ ved alfa-metyl in patients intolerant to alpha-methyldopa.) E. Sa								18
Panel diskusjon. (Panel discussion.) Haakon Storm-			-	-	-	-	_	23
Innledning: doxepin. (Introduction.) Pål Hartvig	-	_	_		_	7	. =	32
Doxepin sammenlignet med cimetidin i behandli påviste duodenalsår. (Doxepin compared with	ngen av	v pas	natie	med	endo	skop	isk nal	
ulcer confirmed by gastroscopy.) T. E. Ruud, G. H						_	iiai 	37
So-called 'tension headache': a term in need of revis	ion? Ot	tar Sj	aastaa	_	_	_	_	41
Panel diskusjon. (Panel discussion.) Pål Hartvig_	-		-	-		-	-	55
Supplement No. 10. Aspects of vertigo							Suppl.	nage
V41-1			rl. r	D			Suppi.	
Vestibular and ocular motor function testing at a dia Staging vertigo and the vertigogram. I. Kaufman Are						Foldn	nan	3
Audiological investigation in vertigo, R. R. A. Coles		run Di	ине и	nu Oce	ngeo	Outil	116474	18
Vertigo in a neurologist's practice. C. H. Edwards	-	_		-		-	_	34
Vertigo in an otologist's practice. JP. Bébéar	-	_	_	_	_			40
The medical management of vertigo, T. J. Wilmot		_	_	_	_		_	43
Surgical management of vertigo. Gordon D. L. Smyt	h and M	Tatthe	w P. 7	homse	011		-	49
The surgical management of acoustic neurinomas.						15		62
	-							

